

Claims

1. A mammal with inducible ductal carcinoma *in situ* (DCIS), wherein the mammal contains an oncogene that can be activated by lactotrophic hormones.
2. The mammal according to claim 1, wherein DCIS develops into an invasive ductal mammary carcinoma.
3. The mammal according to claim 1 or 2, wherein the oncogene is controlled by the WAP promoter.
4. The mammal according to any of claims 1 to 3, wherein the oncogene comprises a sequence coding for a strong T-cell epitope.
5. The mammal according to any of claims 1 to 4, wherein the oncogene is a gene coding for SV40 T-Ag.
6. The mammal according to claim 4 or 5, wherein the sequence codes for the n118 epitope of the LCM virus nucleoprotein.
7. The mammal according to any of claims 1 to 6, wherein the lactotrophic hormones comprise estrogen, prolactin, insulin and hydrocortisone.
8. The mammal according to any of claims 1 to 7, wherein the mammal is that of figures 4, 5, 6, 7, 8 or 9.
9. A method of providing a mammal according to any of claims 1 to 8, comprising the steps of:
  - (a) introducing a DNA coding for an oncogene into inseminated oocytes of a mammal, the DNA being controlled by a promoter specific to lactotrophic hormones,
  - (b) implanting the oocytes from (a) into pseudopregnant mammals, and

- (c) selecting the progeny obtained in (b) for the formation of DCIS.
- 10. The method according to claim 9, wherein the DCIS develops into invasive ductal mammary carcinoma.
- 11. The method according to claim 9 or 10, wherein the promoter is the WAP promoter.
- 12. The method according to any of claims 9 to 11, wherein the oncogene comprises a sequence coding for a strong T-cell epitope.
- 13. The method according to any of claims 9 to 12, wherein the oncogene is a gene coding for SV40 T-Ag.
- 14. The method according to claim 12 or 13, wherein the sequence codes for the n118 epitope of the LCM virus nucleoprotein.
- 15. The method according to any of claims 9 to 14, wherein the lactotrophic hormones comprise estrogen, prolactin, insulin and hydrocortisone.
- 16. The method according to any of claims 9 to 15, wherein the progeny are those of figure 4, 5, 6, 7, 8 or 9.
- 17. Use of the mammal according to any of claims 1 to 9 for studying DCIS, its progression towards an invasive ductal carcinoma and the latter.
- 18. Use of the mammal according to any of claims 1 to 9 for the research and development of diagnostic markers and therapeutic agents for a DCIS or an invasive ductal carcinoma.